Short interest in Emergent BioSolutions Inc (NYSE:EBS) increased during the last reporting period, rising from 6.93M to 7.09M. This put 15.91% of the company's publicly available shares short.

Emergent BioSolutions Inc.'s $40 million class action settlement of claims that it misled investors about its ability to ...

During the last three months, 4 analysts shared their evaluations of Emergent BioSolutions EBS, revealing diverse outlooks from bullish to bearish. The following table provides a quick overview of ...

Welcome to Emergent BioSolutions Inc. Fourth Quarter ... In the US, the public interest channel is backed by over $50 billion in opioid settlement funds from large pharma companies that are ...